Biohaven Ltd.
Company Stats
- Market Cap
- $2.0B
- as of Sep 30, 2026
- Shares Outstanding
- 151.0M
- Free Float
- 99.9%
Income Statement
- Operating Income
- -$745.4M
- Net Income
- -$738.8M
- EBITDA
- -$735.5M
Cash Flow
- Free Cash Flow
- -$610.2M
- FCF Yield
- -30.3%
- Owner FCF Yield
- -35.8%
Balance Sheet
- Cash & Equivalents
- $230.0M
Returns & Capital
- SBC, 3Y Avg
- $71.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$610.2M | — |
| FY2024 | — | -$586.5M | — |
| FY2023 | — | -$334.8M | — |
| FY2022 | — | -$303.8M | — |
| FY2021 | — | -$146.8M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 18, 2026
Weekly Deals
Deals Roundup for Week of Oct. 12, 2026
October 15, 2026
Deals
Biohaven Licenses MoDE Degraders to Ono for Asia
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 27, 2026
Deals
Biohaven to Buy SK Biopharm's Kv7 Assets in $795 Million Deal
Deals Roundup for Week of Oct. 12, 2026
October 15, 2026
Deals
Biohaven Licenses MoDE Degraders to Ono for Asia
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 27, 2026
Deals
Biohaven to Buy SK Biopharm's Kv7 Assets in $795 Million Deal